Immunology
2 drugs are in development for IgA Nephropathy.
- Companies
- 2
- Clinical trials
- 20
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the IgA Nephropathy pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| BHV-1400 | Biohaven Ltd. (BHVN) |
Phase 2(1)
| Drug | Company |
|---|---|
| adx-097 | Q32 Bio Inc. (QTTB) |
About this indication
IgA Nephropathy context
Immunology·MeSH: Glomerulonephritis, IGA (D005922)
Also known as: Berger Disease, Bergers Disease, Glomerulonephritides, IGA, IGA Glomerulonephritis, IGA Type Nephritis, Nephropathy 1, Iga, Nephropathy, Immunoglobulin A
Prevalence
25.0 / 100K
Incidence
2.5 / 100K/yr
Frequently asked questions
How many drugs are in development for IgA Nephropathy?
BioSniper tracks 2 drugs in development for IgA Nephropathy across 2 companies.
How many clinical trials target IgA Nephropathy?
There are 20 clinical trials targeting IgA Nephropathy tracked by BioSniper.
What is the prevalence of IgA Nephropathy?
The estimated prevalence of IgA Nephropathy is approximately 25.0 per 100,000 population.